Clinical Research Directory
Browse clinical research sites, groups, and studies.
Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma
Sponsor: Giselle Sholler
Summary
A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.
Official title: A Beat Childhood Cancer Research Consortium Phase II Trial of Transplant-Free Chemo-immunotherapy Consolidation Regimen With Naxitamab for High-Risk Neuroblastoma
Key Details
Gender
All
Age Range
1 Year - 30 Years
Study Type
INTERVENTIONAL
Enrollment
101
Start Date
2026-11-26
Completion Date
2040-11-26
Last Updated
2026-11-16
Healthy Volunteers
No
Conditions
Interventions
Naxitamab and GM-CSF in combination with irinotecan and temozolomide
anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation
Dinutuximab. Immunotherapy
Dinutuximab + GM-CSF + Isotretinoin (or Dinutuximab-Beta) for 5 cycles plus Isotretinoin alone in Cycle 6
DFMO
DFMO Monotherapy: DFMO for 730 days (2 years)
Locations (1)
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania, United States